Hepatitis Forums
Advanced Liver Disease Main Forums => Advanced Liver Disease => Topic started by: Hep Editors on October 21, 2019, 11:07:35 am
-
The checkpoint inhibitor Opdivo (nivolumab) did not reach the statistical threshold for improved overall survival compared with standard targeted therapy for people with advanced liver cancer, but it did appear to be better tolerated, according to research presented at the European Society for Medical Oncology Congress (ESMO 2019) this week in Barcelona.
The median overall survival was 16.4 months for patients taking Opdivo versus 14.7 months for those using Nexavar (sorafenib) in a late-stage study. Although this difference did not meet the study’s high bar for statistical significance, meaning it could have been driven by chance, people taking Opdivo had fewer severe side effects and were less likely to stop treatment for this reason.
Read more...
https://www.hepmag.com/article/opdivo-shows-mixed-results-liver-cancer